ACOMPLIA now available.Immediately is available ACOMPLIA in Germany and beyond that also in Great Britain, Denmark, Ireland, Finland and Norway one offers.
May 8, 2007 (Press Release) --
ACOMPLIA now available
Immediately is available ACOMPLIA in Germany and beyond that also in Great Britain, Denmark, Ireland, Finland and Norway one offers. The medicine is available for using up as 20-mg tablet, which is taken once on the day before the breakfast.
On 21 June 2006 the European commission had given the permission for ACOMPLIA (Rimonabant 20 mg/day) for all 25 member states of the European Union for the following indication:
Additionally to Diät and movement on the treatment of adiposity (BMI > 30 kg/m2) or over-weighty patients (BMI > 27 kg/m2), which exhibits one or more factors of risk beyond that such as Typ-2-Diabetes or Dyslipidämie.
ACOMPLIA of sanofi aventis one discovered and one developed. It is a first representative of a new class of medicines, the so-called CB1-Antagonisten. Into ACOMPLIA contained active substance the Rimonabant blocks selectively the CB1-Rezeptoren at multiple effect places such as muscles, fatty tissue, liver, stomach, intestine and brain. ACOMPLIA the overactivity of the EC-system restrains and causes in this way a reduction of kardiometabolischer factors of risk like degraded HDL, increased triglycerides, increased HbA1c and increased waist extent:
Over-weighty patients can reduce their body weight clearly by regular income of the new active substance Rimonabant and lower thus their metabolic risk clearly regarding a diabetes or a heart cycle illness. If the effect of the weight reduction could be documented so far only over maximally twelve months, now results of a new study occupy that the reached weight acceptance with Rimonabant can remain also long-term. for more visit http://www.acompliarimonabantpill.co.uk
Immediately is available ACOMPLIA in Germany and beyond that also in Great Britain, Denmark, Ireland, Finland and Norway one offers. The medicine is available for using up as 20-mg tablet, which is taken once on the day before the breakfast.
On 21 June 2006 the European commission had given the permission for ACOMPLIA (Rimonabant 20 mg/day) for all 25 member states of the European Union for the following indication:
Additionally to Diät and movement on the treatment of adiposity (BMI > 30 kg/m2) or over-weighty patients (BMI > 27 kg/m2), which exhibits one or more factors of risk beyond that such as Typ-2-Diabetes or Dyslipidämie.
ACOMPLIA of sanofi aventis one discovered and one developed. It is a first representative of a new class of medicines, the so-called CB1-Antagonisten. Into ACOMPLIA contained active substance the Rimonabant blocks selectively the CB1-Rezeptoren at multiple effect places such as muscles, fatty tissue, liver, stomach, intestine and brain. ACOMPLIA the overactivity of the EC-system restrains and causes in this way a reduction of kardiometabolischer factors of risk like degraded HDL, increased triglycerides, increased HbA1c and increased waist extent:
Over-weighty patients can reduce their body weight clearly by regular income of the new active substance Rimonabant and lower thus their metabolic risk clearly regarding a diabetes or a heart cycle illness. If the effect of the weight reduction could be documented so far only over maximally twelve months, now results of a new study occupy that the reached weight acceptance with Rimonabant can remain also long-term. for more visit http://www.acompliarimonabantpill.co.uk
Email
Print
SPAM
